HLA DR2: A predictive marker in response to cyclosporine therapy in aplastic anemia

International Journal of Hematology

Volumn 66, Issue 3, 1997, Pages 291-295

  Ihan, Osman ^a   Beksaç, Meral ^a   Arslan, Önder ^a   Özcan, Muhit ^a   Koç, Haluk ^a   Akan, Hamdi ^a   Gürman, Günhan ^a   Konuk, Nahide ^a   Uysal, Akin ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Aplastic anemia; Cyclosporine; HLA DR typing; Immunosuppressive therapy

Indexed keywords

CYCLOSPORIN A; HLA DR2 ANTIGEN; LYMPHOCYTE ANTIBODY; THYMOCYTE ANTIBODY;

APLASTIC ANEMIA; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; HLA MATCHING; HLA SYSTEM; HLA TYPING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; TURKEY (REPUBLIC);

EID: 0031258585     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0925-5710(97)00054-6     Document Type: Article

References (14)

1. Rees A.J., Peters D.K., Compston D.A.S., Batchelor J.R. Strong association between HLA-DRw2 and antibody mediated Goodpastures syndrome. Lancet. 1:1978;966-968.
2. Lieberman J.A., Yunis J., Egea E., Canoso R.T., Kane J.M., Yunis E.J. HLA-B38, DR4, Dqw3 and clonazipine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psych. 47:1990;945-950.
3. Nimer S.D., Ireland P., Meshkinpour A., Frane M. An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood. 84:1994;923-927.
4. Rugman F.P., Ashby D., Davies J.M. Does HLA DR predict response to specific immunosuppressive therapy in aplastic anemia? Br J Haematol. 74:1990;545-546.
5. Nakao S., Yamaguchi M., Saito M.et al. HLA DR2 predicts a favourable response to cyclosporine therapy in patients with bone marrow failure. Am J Hematol. 40:1992;239-240.
6. Nakao S., Takamatsu H., Chuhjo T.et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosprine-dependent aplastic anemia. Blood. 84:1994;4257-4261.
7. Nakao S., Takami A., Sugimori A.et al. Response to immunosuppressive therapy and HLA-DRB 1 allele in patients with aplastic anemia: HLA-DRB1*1501 does not predict response to antithymocyte globulin. Br J Haematol. 92:1996;155-158.
8. Camitta B.M., Thomas E.D., Nathan D.G.et al. A prospective study of androgens and marrow transplantation for the treatment of severe aplastic anemia. Blood. 53:1979;504.
9. Bacigalupo A., Broccia G., Corda G.et al. Antilymphocytic globulin, cyclosporin and granulocyte stimulating factor in patients with aquired severe aplastic anemia (SAA): A pilot study of the EBMT SAA working party. Blood. 85:1995;1348-1353.
10. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuki T, editors. HLA 1991 Proceedings of the 11th International Histocompatibility Workshop. Oxford University Press, London, 1992:1065-1220.
11. Chapuisy B., Von Fliedner V.E., Jeannet M.et al. Increased frequency of DR2 in patients with aplastic anemia and increased DR sharing in their parents. Br J Haematol. 63:1986;51-57.
12. Ilhan O., Beksaç M., Koç H. HLA DR frequency in Turkish aplastic anemia patients and the impact of HLA DR2 positivity in response rate in patients receiving immunosuppressive therapy. Blood. 86:1995;2055.
13. Özkan M., Çarin M., Sönmez G., Şenocak M., Özdemir M., Yakut C. HLA antigens in Turkish race with rheumatic heart disease. Circulation. 87:1993;1974-1978.
14. Corzo D., Yunis J.J., Salazar M. The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood. 86:1995;3835-3840.